CXCL8 and non-small cell lung carcinoma: Advanced NSCLC patients who responded well toward nivolumab, a PD-1 targeted treatment, demonstrated low levels of CXCL8, TNF-α, and IP-10 and high levels of BMP-9 compared to non-responders (241).